The effect of TP53 mutations on the clinical outcomes of Ph-negative B-acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.issn.0253-2727.2020.11.005
- VernacularTitle:TP53基因突变对Ph阴性急性B淋巴细胞白血病异基因造血干细胞移植疗效的影响
- Author:
Xingyu CAO
1
;
Yang ZHANG
;
Deyan LIU
;
Jianping ZHANG
;
Zhijie WEI
;
Min XIONG
;
Ruijuan SUN
;
Yue LU
;
Jiarui ZHOU
;
Yanli ZHAO
;
Wei MA
;
Wei ZHANG
Author Information
1. 河北燕达陆道培医院造血干细胞移植科，河北省廊坊市 065201
- Keywords:
TP53 gene;
Leukemia, B lymphoblastic, acute;
Allogeneic hematopoietic stem cell transplantation
- From:
Chinese Journal of Hematology
2020;41(11):908-914
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the association of TP53 mutations with the clinical outcomes of Ph-negative B-ALL following allogeneic hematopoietic stem cell transplantation (allo-HSCT) .Methods:Total 300 patients with Ph-negative B-ALL who underwent allo-HSCT at the Hebei Yanda Ludaopei Hospital from May 2012 to May 2017 were retrospectively analyzed; their clinical characteristics, TP53 gene mutation type, and association between TP53 mutations and transplantation outcomes, including leukemia-free survival (LFS) , overall survival (OS) , non-relapse mortality (NRM) , relapse, and GVHD, were evaluated.Results:Total 23 patients had TP53 mutations; all the TP53 mutations affected P53’DNA-binding domain. The 5-year-LFS, OS, and RI were 34.8% and 62.3% ( P=0.001) , 41.9% and 65.1% ( P=0.020) , and 47.8% and 14.8% ( P=0.000) , respectively, for TP53 mutations and wild-type TP53 patients. However, there were no significant differences in NRM and GVHD. Multivariate analysis showed that TP53 mutations remained adverse prognostic factors for LFS, OS, and RI after allo-HSCT. Conclusion:Some patients with TP53 mutations can achieve long-term survival with allo-HSCT. TP53 mutations are adverse prognostic factors for Ph-negative B-ALL patients who undergo allo-HSCT.
